<DOC>
	<DOCNO>NCT00509431</DOCNO>
	<brief_summary>RATIONALE : Erlotinib sirolimus may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I/II trial study side effect best dose erlotinib give together sirolimus see well work treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Erlotinib Sirolimus Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) escalate dos erlotinib hydrochloride combination sirolimus adult patient malignant glioma , receive enzyme-inducing anti-epileptic drug ( EIAED ) . ( Phase I ) - Evaluate preliminary efficacy ( response rate [ RR ] , progression-free survival [ PFS ] , overall survival [ OS ] ) erlotinib hydrochloride sirolimus combination therapy glioblastoma multiforme ( GMB ) /gliosarcoma ( GS ) patient undergo surgery time recurrence relapse ( dose-expansion arm ) . ( Phase II ) - Evaluate molecular determinant response combination erlotinib hydrochloride sirolimus , especially roles mutation EGFR ( e.g. , vIII mutant , somatic mutation vIII , mutation/deletion PTEN ) . Secondary - To characterize safety tolerability erlotinib hydrochloride sirolimus combination therapy patient population . - To characterize single-dose repeated-dose pharmacokinetic ( PK ) profile erlotinib hydrochloride ( serum ) sirolimus ( whole blood ) combination therapy patient population . - To characterize , pre- and/or post-treatment tumor sample , available , expression level total activate phosphorylated protein relevant EGFR , VEGFR , PI3K/mTOR signal pathway , relevant downstream signal network component , EGFR VEGFR-related ligand , apoptosis ( TUNEL ) , cell cycle control , proliferation . - To assess pre- and/or post-treatment tumor sample , available , DNA-based change ( e.g. , EGFR [ DNA ] amplification , EGFR EGFRvIII mutation , mutations/deletions PTEN gene ) relevant molecular biology GBM . OUTLINE : Patients receive oral erlotinib hydrochloride sirolimus daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo tumor tissue blood sample collection periodically pharmacological biological study . Samples analyze concentration erlotinib hydrochloride trough serum level sirolimus via HPLC , EGFR , EGFRvIII , PTEN phospho-specific antibody associate MAPK PI3K pathways via IHC , EGFRvIII sequence EGFR , PTEN critical gene via PCR , gene expression , SNP analysis . Germline DNA also use distinguish polymorphism somatic mutation gene sequence . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically confirm malignant glioma , include follow : Glioblastoma multiforme ( GBM ) Gliosarcoma ( GS ) Anaplastic astrocytoma ( AA ) Anaplastic oligodendroglioma ( AO ) Anaplastic mixed oligoastrocytomas ( AMA ) Malignant astrocytoma otherwise specify ( NOS ) Prior lowgrade glioma allow provide histologic evidence progression malignant glioma Must meet follow criterion phase I : All type malignant glioma allow No limitation number relapse Must meet follow criterion phase II : Only patient GBM GS allow Must first , second , third relapse patient prior therapy ( must include external beam radiotherapy ) lowgrade glioma consider standard , nonsurgical treatment highgrade glioma , surgical diagnosis highgrade glioma consider first relapse Must show unequivocal radiographic evidence tumor progression MRI CT scan either measurable evaluable disease Measurable disease define bidimensionally measurable lesion clearly define margin MRI scan Evaluable disease define unidimensionally measurable lesion mass margin clearly define Karnofsky performance status ≥ 60 % Life expectancy &gt; 8 week Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/μL Total bilirubin &lt; 2.0 x upper limit institutional normal ( ULN ) AST &lt; 2.0 x ULN Creatinine &lt; 1.5 x ULN Fasting serum triglyceride &lt; 2.5 x ULN Fasting serum cholesterol &lt; 350 mg/dL Women childbearing potential men must agree use adequate contraception ( i.e. , hormonal barrier method birth control ) prior study entry duration study participation Recovered toxicity associate prior surgery , radiotherapy , chemotherapy At least 1 week since prior surgery At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) At least 12 week since prior radiation therapy Must receive P450enzymeinducing anticonvulsant ( EIAC ) least 2 week prior participation trial Women pregnant lactate History allergic reaction attribute compound similar chemical biologic composition erlotinib hydrochloride sirolimus Uncontrolled intercurrent illness include , limited , follow : Ongoing active infection require IV antibiotic Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Hyperlipidemia ( e.g. , grade 3 great hypercholesterolemia hypertriglyceridemia ) control medication Psychiatric illness social situation would limit compliance study requirement Disorders associate significant immunocompromise ( e.g. , HIV systemic lupus erythematosus [ SLE ] ) Patients another primary malignancy require treatment surgery within past year ( except nonmelanoma skin cancer carcinoma situ ) Patients inability comply protocol requirement opinion investigator include take oral medication Patients unable undergo routine imaging evaluation magnetic resonance imaging scan Prior EGFRdirected mTORdirected therapy include sirolimus sirolimus analog Patients take concurrent immunosuppressive agent prescribed corticosteroid Concurrent antineoplastic antitumor agent part study therapy include chemotherapy , radiation therapy , immunotherapy , hormonal anticancer therapy Blood product cycle 1 unless patient experience hematologic DLT medically imperative administer transfusion Concurrent grapefruit grapefruit juice Other concurrent investigational agent Receiving concurrent enzymeinducing antiepileptic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
</DOC>